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with Attention Deﬁcit/Hyperactivity Disorder (ADHD) in
children. The objective of this abstract is to present the
results on the burden (intangible costs) ADHD imposes
on the individual, the family and society in terms of
symptom persistence, violence, antisocial behaviour,
crime, substance misuse, social adjustment, academic 
performance. METHODS: The international literature
search was complemented by country-speciﬁc literature
searches in France, Germany, Italy, Netherlands, Spain
and the UK. In each country a clinical expert was inter-
viewed and reviewed the country-speciﬁc information.
RESULTS: Sources reporting the intangible conse-
quences/costs of ADHD were limited with literature from
the UK, France, Spain and Sweden. Literature suggests
that pervasively hyperactive symptoms in childhood is a
risk factor for poor outcomes in later development with
ADHD symptoms persisting into school leaving age and
nearly half of hyperactive children given a psychiatric
diagnosis. The literature review found reports indicating
that hyperactivity was a determinant of violence, aggres-
sion, deﬁant and disruptive behaviours, stealing, shoplift-
ing, joyriding, vandalism, offending and contact with the
police. Reports suggest a causal link between ADHD and
substance misuse but there is no consensus. Childhood
hyperactivity was reported to be a strong predictor of
relationship problems with links between hyperactivity
and moderate to severe problems in social functioning.
Reports from UK, France and Spain indicate that acade-
mic problems in school were more frequent in children
displaying hyperactive symptoms with language disor-
ders, reading, writing, cognitive and/or social develop-
ment difﬁculties. CONCLUSION: The consequences of
ADHD for the individual are potentially very severe and
we can infer this imposes a signiﬁcant burden upon the
family unit and society. ADHD symptoms can persist into
adolescence, and the hyperactive element of ADHD can
be predictive of violence, antisocial behaviour, crime,
poor social adjustment, substance abuse, and academic
problems.
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OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and cost associated
with Attention Deﬁcit/Hyperactivity Disorder (ADHD) in
children. The objective of this abstract is to present the
results on deﬁnition of the disorder, diagnosis, prevalence,
demographics, age of onset and treatment guidelines,
treatment in Europe. METHODS: The international 
literature search was complemented by country-speciﬁc 
literature searches in France, Germany, Italy, Nether-
lands, Spain and the UK. In each country a clinical expert
was interviewed and reviewed the country-speciﬁc infor-
mation. RESULTS: Across Europe, literature reﬂects 
the use of both the ICD-10 deﬁnition of Hyperkinetic 
Disorder (HD), and the DSM-IV deﬁnition of ADHD. 
In Italy the DSM-III and DSM-IIIR deﬁnitions are also
reported. Diagnosis/treatment initiation is usually made
by child psychologists/psychiatrists and, increasingly, by
paediatricians. Estimates of prevalence vary widely
depending on the study population and diagnostic crite-
ria used. For the general population, estimates based on
the HD deﬁnition are in the range of 0.5–2.4% and those
based on the ADHD deﬁnition are in the range of 5–10%.
Reports from the UK and Germany indicated that features
of the disorder arise before the age of 5 years. One source
from Germany reported that symptom recognition
occurred on average at 10.2 years of age, with 9.4% of
the sample experiencing ﬁrst symptoms at 5 years of age
or younger. European treatment guidelines have been pub-
lished and country speciﬁc treatment guidelines also exist
in the UK, Netherlands, and Germany. Pharmacotherapy
in Europe is primarily through the use of psychostimu-
lants, although these are not generally available in Italy.
CONCLUSION: The literature review established that
ADHD/HD is a recognised disorder for children in Europe.
Formal criteria are used to diagnose the disorder, studies
have measured the prevalence, demographics, age of onset
and treatment guidelines have been published.
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OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and costs associated
with Attention Deﬁcit/Hyperactivity Disorder (ADHD) in
children. The objective of this abstract is to present the
results on deﬁnition, gender characteristics, recognition,
delay between onset and diagnosis. METHODS: The
international literature search was complemented by
country-speciﬁc literature searches in France, Germany,
Italy, Netherlands, Spain and the UK. In each country, a
clinical expert was interviewed and reviewed the country-
speciﬁc information. RESULTS: Deﬁnition of ADHD is
not uniform across countries as the literature reﬂects 
the use of both the ICD-10 deﬁnition of Hyperkinetic 
Disorder (HD), and the DSM-IV deﬁnition of ADHD.
DSM-IV offers a broader, more encompassing deﬁnition
of ADHD when compared to HD. Reports of male to
female prevalence found conﬂicting evidence as male
cases may outnumber females by as much as 9 :1, but
other sources reported a 1 :1 ratio. ADHD/HD differ-
ences in gender is currently debated with the view that
boys exhibit more distinguishable symptoms. The litera-
ture indicated that diagnosis may be complicated by many
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co-morbid disorders. Literature from the UK and 
Netherlands report a delay between ﬁrst contact with a
GP and diagnosis ranging from months to years. One UK
report found that many general practitioners were skep-
tical of ADHD and that parents felt rebuked by the GP
when they ﬁrst presented a hyperactive pre-school child.
One FR speciﬁc report found that of those referred, 62%
had not received any previous medical advice. CON-
CLUSION: Diagnosis may be hindered by co-morbid dis-
orders, GP skepticism of hyperactivity as a behavioural
disorder, and parents feeling they are not taken seriously.
Once recognised as having an emotional/behavioural
problem, referral to a specialist is unlikely resulting in 
signiﬁcant delays between ﬁrst contact with a GP and
diagnosis/treatment. Hence, some sufferers, especially
females, may not be diagnosed.
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OBJECTIVES: To improve quality and persistency of
anti-depressive therapy in primary care by a correspon-
dence course for GPs focusing on interaction between
patient and physician. METHODS: One hundred sixty-
nine depressive patients in two groups were observed in
a cohort study. GPs in the education group (84 patients)
received training material on therapy of depression. A
parallel control group of 85 depressive patients recruited
by physicians not obtaining training material was
observed to compare effectiveness. In both groups
patients were on Citalopram treatment. Measures: 
demographics, prescriptions, Clinical Global Impression
Scale (CGI) and Hamilton Depression Scale (HAM-D).
Additionally, patients were asked to answer questions
concerning their treatment satisfaction and quality of life
(SF-36). They were observed over a 6-month period. For
external comparison of therapy duration to non-study
conditions, data from the prescription database MediPlus
(IMS HEALTH) were analysed. RESULTS: Comparing
the two groups there were no differences in clinical data
(CGI, HAM-D) and quality of life (SF-36). However, the
following differences were found: In comparison to
control group, patients in education group had more con-
tacts to their GP. Especially in the beginning of therapy,
there were shorter intervals between visits. Patients in
education group received anti-depressive medication for
a longer period. In education group the rate of discon-
tinuing the pharmaceutical therapy within the recom-
mended 6-month period was only 36% in comparison to
44% in the control group (reduction of 18%). When
related to MediPlus data, the discontinuation rate was
lowered by 46%. CONCLUSIONS: The IMPROVE-D
training material for GPs improved therapy quality and
persistency. The training resulted in more frequent physi-
cian contacts and careful drug prescription. Patients 
felt more bound to the physician’s instructions and
showed a better compliance. This resulted in a longer
therapy duration which experts link to a reduced risk for
relapsing.
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Published models for schizophrenia in literature are 
generally Markov models, which entail many methodo-
logical disadvantages. OBJECTIVE: To build a disease
progression model for schizophrenia that circumvents the
problems of Markov modelling. The model is designed to
simulate individual histories of schizophrenic patients
from the age of onset until death, but it can easily be
adapted to shorter time horizons. A patient enters the
model when he visits the psychiatrist because he suffers
from a relapse. At each visit the psychiatrist will re-
evaluate the visiting scheme, the patient’s treatment and
his location. Furthermore, the psychiatrist will estimate
the patient’s severity of disease (PANSS, QALY, Danger).
At any time the patient can decide to be non-compliant.
METHODS: The model is characterised by four steps: 1)
deﬁnition and description of patient characteristics, 2)
calculation of the progression of schizophrenia for that
individual patient in each of the compared treatment
strategies, 3) calculation of the costs and effects generated
in each of the strategies; and 4) when previous steps are
performed for a speciﬁc patient population, calculation
of the average medical and economical outcomes per
strategy. RESULTS: The model is able to simulate indi-
vidual patient histories with patient-speciﬁc probabilities.
Unlike Markov models, we do not assume a direct link
between a health state and costs. Moreover, we individu-
alise the relations between what happens to a patient and
the expected costs and effects. Also, we take account 
of unobserved heterogeneity. CONCLUSIONS: The 
outlined model is complex and needs much input. 
Moreover, many estimates are surrounded by uncertain-
ties. However, it needs to be stressed that simpler models
implicitly need the same input, but they hide assumptions
that are explicit in this model. Therefore, the presented
model is subtler, more transparent and closer to clinical
practice.
